Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Status:
NOT_YET_RECRUITING
Trial end date:
2027-08-13
Target enrollment:
Participant gender:
Summary
A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)
Phase:
PHASE2
Details
Lead Sponsor:
Oregon Health and Science University
Collaborators:
Janssen Scientific Affairs, LLC Ohio State University